Description:
· Effective dietary supplement in the treatment of epilepsy in dogs.
Ingredients:
Potassium bromide
Magnesium stearate;
Microcrystalline cellulose.
Key benefits:
· The safest way to treat epilepsy in dogs in the long term.
· In recent years, the use of potassium bromide for the treatment of epilepsy has gained the approval of veterinarians.
· It is particularly beneficial for dogs that show a poor response to phenobarbitone, dogs with liver disease, liver toxicity as a result of the use of phenobarbitone.
Intended for:
· Dogs.
Method of administration:
· Oral administration.
· The capsule can be administered as is or can be opened, mixing its contents with food.
· Do not administer on an empty stomach.
· Administer with regular meals.
Presentation form:
· Box of 60 capsules.
Dosage:
· Loading dose administration protocol
– A total dose of 120mg/kg/day + maintenance dose is administered, administered in four divided doses per day.
– The stable dose at blood level will be reached after 5 days of administration.
– The maintenance dose is continued starting on day 6.
– Side effects such as behavioral changes and/or ataxia may be observed.
– Medical supervision is recommended during the administration of the loading dose to avoid overdose and the occurrence of toxicity.
· Maintenance dose:
– Administered with phenobarbital – 25 -40mg/kg/day
– Administered as a single therapeutic agent 50 -80mg/kg/day
– Stable serum levels are obtained after 4 months of administration.
– After one month of administration, the percentage of stability is 60%, which allows dose adjustment.
– The gradual reduction of phenobarbital can be done after two months of continuous therapy with Epilease.
– Usually a single daily administration is recommended.
– If Gastro-Intestinal disorders occur (e.g. vomiting) the dose will be administered in two doses.
Possible adverse effects:
· Ataxia, lethargy and vomiting.
· If you notice serious reactions or other unusual elements, please inform your veterinarian.


Reviews
There are no reviews yet.